^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor) +
    Orpathys (savolitinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

    Published date:
    10/14/2020
    Excerpt:
    Savolitinib 600 mg plus gefitinib 250 mg once daily had an acceptable safety profile and demonstrated promising antitumor activity in EGFRm, MET-amplified advanced NSCLC patients who had disease progression on EGFR-TKIs.
    DOI:
    10.1007/s10637-020-01010-4
    Trial ID:
    NCT02374645